Timeline – gabarx.com

GRX-917 (Improved Etifoxine) Patent Issues

Richard Farrell — Tue, 25 Sep 2018 21:51:22 +0000

Researchers improved etifoxine using deuteration technology by reducing its dosing requirements. The US patent to the new and improved etifoxine issued on September 25, 2018.

Compared etifoxine to lorazepam (Ativan®) – for alertness and cognitive functions in elderly patients

Richard Farrell — Thu, 17 May 2018 21:28:56 +0000

Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study
D. Deplanque, F. Machuron, N. Waucquier, E. Jozefowicz, S. Duhem, S. Somers, O. Colin, A. Duhamel, R. Bordet

Safety Profile of Etifoxine: A French Pharmacovigilance Survey

Richard Farrell — Fri, 13 Nov 2015 21:39:41 +0000

Adverse drug reactions (ADRs) from over 14 million prescriptions of (Stresam®) etifoxine were reviewed and analyzed by the French National Agency for the Safety of Medicines and Health Products, between 2000 and 2012. The average incidence of ADRs was 0.0021% (21 per million treatments) and no cases of abuse, misuse or pharmacodependance were reported.

Compared etifoxine to alprazolam (Xanax®) – for safety and efficacy

Richard Farrell — Tue, 27 Jan 2015 20:31:04 +0000

Etifoxine Versus Alprazolam for the Treatment of Adjustment Disorder with Anxiety: a Randomized Controlled Trial
Dan J. Stein

French 2009 Study – Found it is Safe to Drive on Etifoxine

Richard Farrell — Sun, 01 Mar 2009 21:17:04 +0000

A French study in 2009 found that Etifoxine was safe to drive on, classify it as Level 1 for the purposes of driving a vehicle.

Compared etifoxine to lorazepam (Ativan®) – established non-inferiority in adjustment disorder with anxiety ADWA

Richard Farrell — Thu, 19 Jan 2006 20:27:14 +0000

Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice
N. Nguyen, E. Fakra, V. Pradel, E. Jouve, C. Alquier, M-E. Le Guern, J. Micallef, and O. Blin

Researchers Discover Etifoxine Enhances Neurosteroids

Richard Farrell — Wed, 13 Apr 2005 22:27:33 +0000

French researchers discovered that etifoxine has a dual mechanism of action:
A) it works at GABA channels, and
B) it increases neurosteroids more effectively than any other known compound.

Compared etifoxine with lorazepam (Ativan®) – for sedative and amnesic effects

Richard Farrell — Thu, 29 Mar 2001 20:53:00 +0000

A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects
J. Micallef, C. Soubrouillarda, F. Gueta, M. E. Le Guernb, C. Alquierb, B. Bruguerollea, O. Blin

Etifoxine Patents Expire – Before its True Efficacy was Discovered

Richard Farrell — Tue, 01 Jan 1985 21:05:03 +0000

Etifoxine’s patents expired during the mid 1980’s, before the drug’s true efficacy or mechanism of action was discovered. This explains why Etifoxine was never introduced into the United States or other major markets.

Etifoxine Approved for Anxiety in France

Richard Farrell — Mon, 01 Jan 1979 21:01:42 +0000

A small French distributor developed etifoxine for anxiety in France under the tradename Stresam and subsequently distributed the product throughout Eastern Europe, South America, South Africa and other small regions.